恩赛特韦(Ensitrelvir)用法用量？

The recommended usage and dosage of Ensitrelvir is generally 375 mg orally per day for children and adults over 12 years old, and 125 mg orally on days 2 to 5. The specification of the overseas version of Ensitrelvir is 125mg*28 tablets, that is, 3 tablets are taken orally on the first day, and 1 tablet is taken orally on the 2nd to 5th day. The effectiveness of this agent is presumed in patients who start taking it on the third day after symptoms are discovered. Dosing should be started promptly after symptoms of SARS-CoV-2 infection (new coronavirus infection) appear. It is recommended that patients take medication as directed by their doctor and receive symptomatic treatment.

Ensitrelvir was developed by Japan's Shionogi Pharmaceutical Company. The fluorine-containing medicine has the characteristics of high efficiency and safety. It has been approved for marketing by Japan's Ministry of Health, Labor and Welfare on December 22, 2022, and its scope of application covers people over 12 years old. However, Ensitrelvir is not currently on the market in China, and patients cannot buy it in domestic hospital pharmacies. Patients in need can purchase it abroad or obtain it through domestic professional overseas medical service organizations (such as Medical Companion Travel).

Overseas drugs obtained through domestic professional overseas medical service institutions can be guaranteed to be genuine. Signing a drug protection contract will provide patients with more assurance in obtaining overseas drugs. Moreover, it is delivered directly to the door, which is cost-effective, and patients can obtain overseas medicines without leaving home. However, overseas drug prices are not fixed due to exchange rate fluctuations. It is recommended to consult customer service personnel for the specific cost and acquisition process of Ensitrelvir.

It has a good effect on ordinary patients with mild to moderate symptoms. Infected people who take Ensitrelvir not only have a shorter time to turn negative, but also can greatly reduce the probability of spreading the new coronavirus. Clinical trial results show that the drug has a significant improvement effect on the five typical symptoms of COVID-19 (new coronavirus) of the Omicron strain, has significant antiviral efficacy, and has good safety. Ping An Shionogi has submitted relevant preparation materials for the new drug marketing application of Ensitrelvir to the Drug Evaluation Center of the National Medical Products Administration of China.

Recommended related articles: